HUMAN cDNA SEQUENCES OF UNKNOWN UTILITY SHOULD REMAIN UNPATENTABLE
HUMAN cDNA SEQUENCES OF UNKNOWN UTILITY SHOULD REMAIN UNPATENTABLE by either the National Institutes of Health or the private sector, NIH Director Harold Varmus asserted at the Jan. 24 meeting of the National Advisory Council for Human Genome Research in Washington, D.C. Varmus noted that NIH's institutional position on the patentability of cDNA sequences for which the function is unknown is still being developed. However, he said that his personal view is that "none of these sequences by themselves ought to be patentable."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth